112 related articles for article (PubMed ID: 3391874)
21. The bioavailability of erythromycin stearate versus enteric-coated erythromycin base when taken immediately before and after food.
Clayton D; Leslie A
J Int Med Res; 1981; 9(6):470-7. PubMed ID: 7319133
[TBL] [Abstract][Full Text] [Related]
22. Comparative liver toxicity of various erythromycin derivatives in animals.
Viluksela M; Hanhijärvi H; Husband RF; Kosma VM; Collan Y; Männistö PT
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():9-27. PubMed ID: 3391880
[TBL] [Abstract][Full Text] [Related]
23. Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.
Marvola M; Nykänen S; Nokelainen M
Pharm Res; 1991 Aug; 8(8):1056-8. PubMed ID: 1656422
[TBL] [Abstract][Full Text] [Related]
24. Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora.
Kaukoranta-Tolvanen SS; Renkonen OV; Gordin A; Tamm L; Männistö PT
Scand J Infect Dis; 1989; 21(6):717-20. PubMed ID: 2617212
[TBL] [Abstract][Full Text] [Related]
25. Tolerance and efficacy of erythromycin stearate tablets versus enteric-coated erythromycin base capsules in the treatment of patients with acne vulgaris.
Bleeker J
J Int Med Res; 1983; 11(1):38-41. PubMed ID: 6219902
[TBL] [Abstract][Full Text] [Related]
26. Erythromycin absorption in healthy volunteers from single and multiple doses of enteric-coated pellets and tablets.
Hovi T; Josefsson K; Renkonen OV
Eur J Clin Pharmacol; 1983; 25(2):271-3. PubMed ID: 6628511
[TBL] [Abstract][Full Text] [Related]
27. Effect of food on absorption of erythromycin. A study of two derivatives, the stearate and the base.
Malmborg AS
J Antimicrob Chemother; 1979 Sep; 5(5):591-9. PubMed ID: 500517
[TBL] [Abstract][Full Text] [Related]
28. [Erythromycin pharmacokinetics in children after rectal and oral administration].
Nazarov AD; Strachunskiĭ LS; Firsov AA; Petrachenkova NA; Sushkova VI; Sheliakina RD; Kagan EZ; Nesterova LIa; Sinitsyna NI
Antibiot Khimioter; 1991 Feb; 36(2):36-9. PubMed ID: 2025118
[TBL] [Abstract][Full Text] [Related]
29. Time course of the antibacterial activity of erythromycin stearate and erythromycin acistrate against two Staphylococcus aureus strains in vitro.
Korkeala H; Männistö PT
J Antimicrob Chemother; 1988 Aug; 22(2):127-33. PubMed ID: 3182415
[TBL] [Abstract][Full Text] [Related]
30. Absorption of various erythromycin esters and salts in mice after intragastric intubation.
Vainio PJ; Viluksela M; Männistö PT
Methods Find Exp Clin Pharmacol; 1992 Jun; 14(5):367-72. PubMed ID: 1513192
[TBL] [Abstract][Full Text] [Related]
31. Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
Welling PG; Elliott RL; Pitterle ME; Corrick-West HP; Lyons LL
J Pharm Sci; 1979 Feb; 68(2):150-5. PubMed ID: 423080
[TBL] [Abstract][Full Text] [Related]
32. Hydrolysis of 2'-esters of erythromycin.
Taskinen J; Ottoila P
J Antimicrob Chemother; 1988 Jun; 21 Suppl D():1-8. PubMed ID: 3391870
[TBL] [Abstract][Full Text] [Related]
33. Human pharmacokinetics of erythromycin propionate-N-acetylcysteinate: comparative evaluation with erythromycin stearate and N-acetylcysteine.
De Bernardi M; Feletti F; Gazzani G; Fregnan GB
Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):444-7. PubMed ID: 3198299
[TBL] [Abstract][Full Text] [Related]
34. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
35. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
[TBL] [Abstract][Full Text] [Related]
36. Dependence between dissolution rate and porosity of compressed erythromycin acistrate tablets.
Riippi M; Yliruusi J; Niskanen T; Kiesvaara J
Eur J Pharm Biopharm; 1998 Sep; 46(2):169-75. PubMed ID: 9795044
[TBL] [Abstract][Full Text] [Related]
37. Intra- and intersubject variation of erythromycin absorption from single-unit and multiple-unit enteric-coated products.
Graffner C; Josefsson K; Stockman O
Biopharm Drug Dispos; 1986; 7(2):163-71. PubMed ID: 3708122
[TBL] [Abstract][Full Text] [Related]
38. Gastric acid inactivation of erythromycin stearate in solid dosage forms.
Boggiano BG; Gleeson M
J Pharm Sci; 1976 Apr; 65(4):497-502. PubMed ID: 5588
[TBL] [Abstract][Full Text] [Related]
39. Selection of an oral erythromycin product.
Fraser DG
Am J Hosp Pharm; 1980 Sep; 37(9):1199-205. PubMed ID: 6998290
[TBL] [Abstract][Full Text] [Related]
40. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
Ahmad M; Pervaiz F
Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
